Pharmaceutical Technology & Development, AstraZeneca , Macclesfield, U.K.
Institute of Pharmaceutical Technology, Goethe University , Frankfurt am Main, Germany.
Mol Pharm. 2017 Dec 4;14(12):4192-4201. doi: 10.1021/acs.molpharmaceut.7b00198. Epub 2017 Aug 23.
Dissolution testing with biorelevant media has become widespread in the pharmaceutical industry as a means of better understanding how drugs and formulations behave in the gastrointestinal tract. Until now, however, there have been few attempts to gauge the reproducibility of results obtained with these methods. The aim of this study was to determine the interlaboratory reproducibility of biorelevant dissolution testing, using the paddle apparatus (USP 2). Thirteen industrial and three academic laboratories participated in this study. All laboratories were provided with standard protocols for running the tests: dissolution in FaSSGF to simulate release in the stomach, dissolution in a single intestinal medium, FaSSIF, to simulate release in the small intestine, and a "transfer" (two-stage) protocol to simulate the concentration profile when conditions are changed from the gastric to the intestinal environment. The test products chosen were commercially available ibuprofen tablets and zafirlukast tablets. The biorelevant dissolution tests showed a high degree of reproducibility among the participating laboratories, even though several different batches of the commercially available medium preparation powder were used. Likewise, results were almost identicalbetween the commercial biorelevant media and those produced in-house. Comparing results to previous ring studies, including those performed with USP calibrator tablets or commercially available pharmaceutical products in a single medium, the results for the biorelevant studies were highly reproducible on an interlaboratory basis. Interlaboratory reproducibility with the two-stage test was also acceptable, although the variability was somewhat greater than with the single medium tests. Biorelevant dissolution testing is highly reproducible among laboratories and can be relied upon for cross-laboratory comparisons.
生物相关介质的溶出度测试在制药行业已经得到广泛应用,是一种更好地了解药物和制剂在胃肠道中行为的方法。然而,到目前为止,人们很少尝试评估这些方法获得的结果的重现性。本研究旨在使用桨法装置(USP 2)确定生物相关溶出度测试的实验室间重现性。13 家工业实验室和 3 家学术实验室参与了这项研究。所有实验室都提供了运行测试的标准方案:在 FaSSGF 中进行溶出度测试以模拟胃中的释放,在单一肠内介质 FaSSIF 中进行溶出度测试以模拟小肠中的释放,以及“转移”(两阶段)方案以模拟从胃环境到肠环境条件变化时的浓度分布。所选的测试产品为市售布洛芬片剂和扎鲁司特片剂。生物相关溶出度测试显示,即使使用了几个不同批次的市售介质制备粉末,参与实验室之间的重现性也很高。同样,商业生物相关介质和内部生产的介质之间的结果几乎相同。将结果与之前的环试验结果进行比较,包括使用 USP 校准片剂或单一介质中的市售药物进行的试验,生物相关研究的结果在实验室间具有高度的重现性。两阶段测试的实验室间重现性也可以接受,尽管与单一介质测试相比,变异性稍大。生物相关溶出度测试在实验室之间具有高度的重现性,可以用于实验室间的比较。